

Melanoma Cancer Pathways

Patient Name: _____ **Date of Birth:** _____
Member ID: _____ **Treatment Start Date:** _____
Stage: _____ **Pathology:** _____
ECOG Status: 1 2 3 4 **ICD-10 Code:** _____

Line of Therapy:
 Neoadjuvant/Pre-op Adjuvant/Post Op 1st Line 2nd Line 3rd Line 3rd Line+ Maintenance

Biomarkers/Attributes: (select all that apply)

c-KIT mutation: <input type="checkbox"/> Exon 11 present <input type="checkbox"/> Exon 9 present <input type="checkbox"/> Not Reported <input type="checkbox"/> No mutation	Prior use of anti-PD-1 agents: <input type="checkbox"/> No <input type="checkbox"/> Yes <input type="checkbox"/> Not Reported		
	BRAF: <input type="checkbox"/> V600E Mutation <input type="checkbox"/> V600K Mutation <input type="checkbox"/> Not Reported <input type="checkbox"/> Wild Type (no mutation)		
NTRK-Fusion: <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Reported			
NRAS mutation: <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Not Reported			

Adjuvant (Resectable)

- Pembrolizumab
- Nivolumab
- Dabrafenib + Trametinib (BRAF mutation)

Adjuvant (Resectable – metastatic)

- Pembrolizumab
- Nivolumab
- Nivolumab + Ipilimumab

Metastatic/Unresectable | First Lines of Therapy

- Nivolumab
- Pembrolizumab
- Nivolumab + Ipilimumab
- Vemurafenib + Cobimetinib (BRAF mutation)
- Dabrafenib + Trametinib (BRAF mutation)
- Encorafenib + Binimetinib (BRAF mutation)

Metastatic/Unresectable | Second and Subsequent Lines of Therapy

- Nivolumab
- Pembrolizumab
- Nivolumab + Ipilimumab
- Encorafenib + Binimetinib (BRAF mutation)

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.



References:

Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. *J Clin Oncol*. 2015;33(25):2780-2788. doi:10.1200/JCO.2014.58.3377

Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741

Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial [published correction appears in *Lancet Oncol*. 2021 Oct;22(10):e428]. *Lancet Oncol*. 2020;21(11):1465-1477. doi:10.1016/S1470-2045(20)30494-0

Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol*. 2017;18(5):611-622. doi:10.1016/S1470-2045(17)30231-0

Ascierto PA, Dummer R, Gogas HJ, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. *Eur J Cancer*. 2020;126:33-44. doi:10.1016/j.ejca.2019.11.016

Ascierto PA, Long GV, Robert C, et al. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial [published correction appears in *JAMA Oncol*. 2019 Feb 1;5(2):271]. *JAMA Oncol*. 2019;5(2):187-194. doi:10.1001/jamaoncol.2018.4514

Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2016;17(9):1248-1260. doi:10.1016/S1470-2045(16)30122-X

Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. *J Clin Oncol*. 2008;26(35):5748-5754. doi:10.1200/JCO.2008.17.5448

Byers BA, Temple-Oberle CF, Hurdle V, McKinnon JG. Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review. *J Surg Oncol*. 2014;110(6):770-775. doi:10.1002/jso.23702

Carlino MS, Menzies AM, Atkinson V, et al. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. *Clin Cancer Res*. 2020;26(19):5086-5091. doi:10.1158/1078-0432.CCR-20-0177

Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. *JAMA*. 2011;305(22):2327-2334. doi:10.1001/jama.2011.746

Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. *J Clin Oncol*. 1999;17(9):2745-2751. doi:10.1200/JCO.1999.17.9.2745

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. *Ann Oncol.* 2017;28(10):2581-2587. doi:10.1093/annonc/mdx339

Chesney J, Puzanov I, Collichio F, et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. *J Clin Oncol.* 2018;36(17):1658-1667. doi:10.1200/JCO.2017.73.7379

DOI: 10.1200/JCO.2020.38.15_suppl.10004 *Journal of Clinical Oncology* 38, no. 15_suppl (May 20, 2020) 10004-10004.

DOI: 10.1200/JCO.2021.39.15_suppl.9516 *Journal of Clinical Oncology* 39, no. 15_suppl (May 20, 2021) 9516-9516.

DOI: 10.1200/JCO.2021.39.15_suppl.9504 *Journal of Clinical Oncology* 39, no. 15_suppl (May 20, 2021) 9504-9504.

Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *N Engl J Med.* 2018;378(8):731-739. doi:10.1056/NEJMoa1714448

Drilon A, Siena S, Ou SI, et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). *Cancer Discov.* 2017;7(4):400-409. doi:10.1158/2159-8290.CD-16-1237

Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 2018;19(5):603-615. doi:10.1016/S1470-2045(18)30142-6

Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2017;18(4):435-445. doi:10.1016/S1470-2045(17)30180-8

Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial [published correction appears in *Lancet Oncol.* 2015 Jun;16(6):e262] [published correction appears in *Lancet Oncol.* 2016 Jun;17(6):e223]. *Lancet Oncol.* 2015;16(5):522-530. doi:10.1016/S1470-2045(15)70122-1

Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy [published correction appears in *N Engl J Med.* 2018 Nov 29;379(22):2185]. *N Engl J Med.* 2016;375(19):1845-1855. doi:10.1056/NEJMoa1611299

Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. *N Engl J Med.* 2018;378(19):1789-1801. doi:10.1056/NEJMoa1802357

Eggermont AMM, Blank CU, Mandala M, et al. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. *J Clin Oncol.* 2020;38(33):3925-3936. doi:10.1200/JCO.20.02110

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Ferrucci PF, Di Giacomo AM, Del Vecchio M, et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. *J Immunother Cancer*. 2020;8(2):e001806. doi:10.1136/jitc-2020-001806

Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in *Lancet*. 2020 Aug 15;396(10249):466]. *Lancet*. 2020;395(10240):1835-1844. doi:10.1016/S0140-6736(20)30934-X

Hamid O, Ilaria R Jr, Garbe C, et al. A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. *Cancer*. 2014;120(13):2016-2024. doi:10.1002/cncr.28635

Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. *Ann Oncol*. 2019;30(4):582-588. doi:10.1093/annonc/mdz011

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*. 2012;380(9839):358-365. doi:10.1016/S0140-6736(12)60868-X

Hersh EM, O'Day SJ, Ribas A, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. *Cancer*. 2010;116(1):155-163. doi:10.1002/cncr.24720

Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial [published correction appears in *Lancet Oncol*. 2018 Dec;19(12):e668] [published correction appears in *Lancet Oncol*. 2018 Nov;19(11):e581]. *Lancet Oncol*. 2018;19(11):1480-1492. doi:10.1016/S1470-2045(18)30700-9

Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma [published correction appears in *N Engl J Med*. 2010 Sep 23;363(13):1290]. *N Engl J Med*. 2010;363(8):711-723. doi:10.1056/NEJMoa1003466

Keilholz U, Ascierto PA, Dummer R, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. *Ann Oncol*. 2020;31(11):1435-1448. doi:10.1016/j.annonc.2020.07.004

Kottschade LA, Suman VJ, Amatruda T 3rd, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). *Cancer*. 2011;117(8):1704-1710. doi:10.1002/cncr.25659

Kroon HM, Huismans AM, Kam PC, Thompson JF. Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review. *J Surg Oncol*. 2014;109(4):348-351. doi:10.1002/jso.23553

Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N Engl J Med*. 2014;371(20):1867-1876. doi:10.1056/NEJMoa1408868

Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N Engl J Med*. 2019;381(16):1535-1546. doi:10.1056/NEJMoa1910836

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Larkin J, Minor D, D'Angelo S, et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. *J Clin Oncol*. 2018;36(4):383-390. doi:10.1200/JCO.2016.71.8023

Lebbé C, Meyer N, Mortier L, et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. *J Clin Oncol*. 2019;37(11):867-875. doi:10.1200/JCO.18.01998

Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. *N Engl J Med*. 2017;377(19):1813-1823. doi:10.1056/NEJMoa1708539

Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *N Engl J Med*. 2014;371(20):1877-1888. doi:10.1056/NEJMoa1406037

McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncol*. 2014;15(3):323-332. doi:10.1016/S1470-2045(14)70012-9

Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol*. 2019;30(12):1884-1901. doi:10.1093/annonc/mdz411

Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma [published correction appears in *J Clin Oncol* 2000 Jun;18(11):2351]. *J Clin Oncol*. 2000;18(1):158-166. doi:10.1200/JCO.2000.18.1.158

Nieweg OE, Kroon BB. Isolated limb perfusion with melphalan for melanoma. *J Surg Oncol*. 2014;109(4):332-337. doi:10.1002/jso.23558

"Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. *Cancer*. 2006;106(2):375-382. doi:10.1002/cncr.21611

ODR: duration of TX"

Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma [published correction appears in *JAMA*. 2016 Jun 14;315(22):2472]. *JAMA*. 2016;315(15):1600-1609. doi:10.1001/jama.2016.4059

Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. *Lancet Oncol*. 2019;20(9):1239-1251. doi:10.1016/S1470-2045(19)30388-2

Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. *Lancet Oncol*. 2019;20(9):1239-1251. doi:10.1016/S1470-2045(19)30388-2

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. *N Engl J Med*. 2015;372(26):2521-2532. doi:10.1056/NEJMoa1503093

Scarfi F, Patrizi A, Veronesi G, et al. The role of topical imiquimod in melanoma cutaneous metastases: A critical review of the literature. *Dermatol Ther*. 2020;33(6):e14165. doi:10.1111/dth.14165

Seth R, Messersmith H, Kaur V, et al. Systemic Therapy for Melanoma: ASCO Guideline. *J Clin Oncol*. 2020;38(33):3947-3970. doi:10.1200/JCO.20.00198

Shi VY, Tran K, Patel F, et al. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series. *J Am Acad Dermatol*. 2015;73(4):645-654. doi:10.1016/j.jaad.2015.06.060

Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. *Clin Cancer Res*. 2008;14(17):5610-5618. doi:10.1158/1078-0432.CCR-08-0116

Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *N Engl J Med*. 2012;366(8):707-714. doi:10.1056/NEJMoa1112302

Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *N Engl J Med*. 2017;377(19):1824-1835. doi:10.1056/NEJMoa1709030

Zimmer L, Livingstone E, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2020;395(10236):1558-1568. doi:10.1016/S0140-6736(20)30417-7

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.